Peptide Therapy Guide

The peptide market moved fast between 2024 and 2026: GLP-1 demand reshaped supply, several vendors shut down, and manufacturers invested in new synthesis and purification capacity. This chapter collects those developments.

Most peptide therapy in the US is now delivered by telehealth. This chapter covers how remote prescribing works, state licensing limits, and how telehealth compares with in-person care.

Immune-modulating peptides have the longest clinical history of the research-stage groups, but most human data comes from outside the US.

PT-141 (bremelanotide) is the only FDA-approved entry here; the remainder are research-stage or prescribed off-label.

Cosmetic peptides are the one group where topical delivery is the norm rather than the exception, which changes both the safety profile and the regulatory picture.

Nootropic and neuropeptide compounds are mostly studied outside the US, and much of the human literature is small or uncontrolled.

Longevity peptides are the most speculative group in this guide: mechanistic rationale is strong, human outcome data is thin.

BPC-157, TB-500 and the blended products built from them dominate this category. The evidence base is overwhelmingly preclinical, and regulatory status is the practical constraint.

This group splits cleanly in two: FDA-approved secretagogues such as sermorelin and tesamorelin, and a much larger set of research-stage compounds sold for physique and recovery goals.

The metabolic class is the only group in this guide with large, completed human trials behind it — GLP-1 receptor agonists are approved medicines with defined titration schedules. The other compounds here are investigational.